Safety and Tolerability of More than Six Days of Tedizolid Treatment-Reference-Cited by-同舟云学术

Safety and Tolerability of More than Six Days of Tedizolid Treatment

Published:2020-06-23 Issue:7 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Mensa Vendrell Mireia¹^ORCID,Tasias Pitarch Maria²,Salavert Lletí Miguel²,Calabuig Muñoz Eva²,Morata Ruiz Laura³,Castells Lao Genís⁴^ORCID,López Suñé Ester⁴,Mensa Pueyo Jose³,Oltra Sempere Maria Rosa⁵,Pedro-Botet Montoya Maria-Luisa⁶,Isernia Valentina⁶,Reynaga Sosa Esteban Alberto⁶,Moreno Nuñez Leonor⁷,Pasquau Liaño Juan⁸,Sequera Arquelladas Sergio⁸,Yuste Ara José Ramón⁹^ORCID,Soriano Viladomiu Alex³

Affiliation:

1. Pharmacy Department, Hospital Plató, Barcelona, Spain

2. Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain

3. Department of Infectious Diseases, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

4. Pharmacy Department, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

5. Department of Infectious Diseases, Hospital Clínico Universitario de València, Valencia, Spain

6. Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain

7. Department of Infectious Diseases, Hospital Universitario Fundación Alcorcón, Madrid, Spain

8. Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain

9. Department of Infectious Diseases, Clínica Universidad de Navarra, Navarra, Spain

Abstract

Tedizolid has demonstrated its efficacy and safety in clinical trials; however, data concerning its tolerability in long-term treatments are scarce. The aim of the study was to assess the indications and to describe the long-term safety profile of tedizolid. A multicentric retrospective study of patients who received tedizolid for more than 6 days was conducted. Adverse events (AEs) were identified from patients’ medical records and laboratory data. The World Health Organization causality categories were used to discern AEs that were probably associated with tedizolid.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00356-20

Reference35 articles.

1. Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections

2. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

3. Platelet Profile in Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid or Linezolid: Findings from the Phase 3 ESTABLISH Clinical Trials

4. Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections

5. Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of serotonin syndrome in patients receiving tedizolid and concomitant serotonergic agents;Antimicrobial Agents and Chemotherapy;2024-09-05

2. Pharmacotherapies for multidrug-resistant gram-positive infections: current options and beyond;Expert Opinion on Pharmacotherapy;2024-05-23

3. Analyse pharmacologique du traitement des pneumopathies à Mycobacterium abscessus;Revue des Maladies Respiratoires;2024-01

4. Safety and tolerability of tedizolid as oral treatment for bone and joint infections;Microbiology Spectrum;2023-10-17

5. In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates;International Journal of Antimicrobial Agents;2023-10